Synchronous Malignancies Identified by 18F-fluciclovine Positron Emission Tomography for Prostate Cancer: Case Series and Mini-Review

Academic Article

Abstract

  • © 2020 Elsevier Inc. Positron emission tomography using the fluorine-18 (18F) fluciclovine radiotracer has been approved for use in recurrent prostate cancer and is a useful tool for clinical decision making. However, 18F-fluciclovine is not specific for prostate cancer tumor cells, and false-positive results have been reported. In the present study, we have reported our experience with synchronous malignancies identified using 18F-fluciclovine and reviewed other reported cases, with a special emphasis on highlighting the clinical decisions that led to the correct diagnosis.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Hoyle JM; Lenzie A; Galgano SJ; McConathy JE; Rais-Bahrami S; Nix JW; McDonald AM